Table 3:
Clinical information summarized for whole prostates and MRS-scanned prostate samples.
| Organs | MRS samples | ||||
|---|---|---|---|---|---|
| Cancer | Benign | ||||
| samples (n) median (range) | total | 10 | 26 | 134 | |
| per organ | - | 1.5 (0–9) | 14.5 (7–16) | ||
| Weight (g) median (range) | 50.5 (33.8–70) | - | - | ||
| Vol (cm3) median (range) | 92 (33.75–141.75) | - | - | ||
| Tissue composition (%) median (range) | cancer | 27.5 (10–90) | 19.67 (2–100) | - | |
| benign glands | - | 7.83 (0–31.25) | 9.5 (0–56.27) | ||
| stroma | - | 66.37 (0–83.75) | 90.50 (43.75–100) | ||
| Gleason Score (GS) | low | 3+3 | 1 | 10 | - |
| 3+4 | 4 | 4 | - | ||
| high | 4+3 | 1 | - | - | |
| 4+4 | 1 | 3 | - | ||
| 4+5 | 2 | - | - | ||
| 5+5 | 1 | 9 | - | ||
| Pathological stage (pTNM) | tumor stage | pT2a | 1 | - | - |
| pT2c | 5 | - | - | ||
| pT3a | 3 | - | - | ||
| pT3b | 1 | - | - | ||
| lymph node stage | N1 | 2 | - | - | |
| N0 | 6 | - | - | ||
| NX | 2 | - | - | ||
| Perineural Invasion | 9 | - | - | ||